Results 161 to 170 of about 1,516,429 (359)

Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2Akita diabetic mouse [PDF]

open access: yes, 2015
Current therapies that target vascular endothelial growth factor (VEGF) have become a mainstream therapy for the management of diabetic macular oedema. The treatment involves monthly repeated intravitreal injections of VEGF inhibitors.
Ali, Imran HA.   +3 more
core   +2 more sources

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang   +8 more
wiley   +1 more source

Towards Motion Compensation in Autonomous Robotic Subretinal Injections [PDF]

open access: yesarXiv
Exudative (wet) age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, typically treated with intravitreal injections. Emerging therapies, such as subretinal injections of stem cells, gene therapy, small molecules and RPE cells require precise delivery to avoid damaging delicate retinal structures. Robotic systems can
arxiv  

Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection. [PDF]

open access: yes, 2014
Background: The number of patients who have undergone intravitreal injections has increased enormously in recent years, but a consensus is still lacking on prophylaxis for endophthalmitis.
Arias Barquet, Lluís   +4 more
core   +2 more sources

The short-needle intravitreal injection technique

open access: yesInternational Journal of Ophthalmology, 2016
PubMed ID ...
Akkin, Cezmi   +3 more
openaire   +4 more sources

Real‐World 10‐Year Outcomes of Anti‐VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background This study examines the long‐term effectiveness of anti‐VEGF therapy in managing neovascular age‐related macular degeneration (nAMD). Despite the well‐established short‐term improvements of anti‐VEGF therapy, there is limited data on its continued efficacy over extended periods.
Kimberly Spooner   +5 more
wiley   +1 more source

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

open access: yesBritish Journal of Ophthalmology, 2014
Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.
R. Avery   +11 more
semanticscholar   +1 more source

Predicting Diabetic Macular Edema Treatment Responses Using OCT: Dataset and Methods of APTOS Competition [PDF]

open access: yesarXiv
Diabetic macular edema (DME) significantly contributes to visual impairment in diabetic patients. Treatment responses to intravitreal therapies vary, highlighting the need for patient stratification to predict therapeutic benefits and enable personalized strategies.
arxiv  

Home - About - Disclaimer - Privacy